CP-673451 is a potent and selective inhibitor of the platelet-derived growth factor receptor (PDGFR) family, particularly PDGFRβ. It is primarily used in research settings to study signaling pathways involved in cell proliferation, survival, and migration. Due to its ability to block PDGFR-mediated signaling, it has been employed in preclinical studies investigating tumor growth and angiogenesis, especially in cancers where PDGFR overexpression plays a role, such as glioblastoma, sarcomas, and certain leukemias. The compound is also utilized to explore the involvement of PDGFR in non-oncological conditions, including fibrosis and vascular remodeling. Its selectivity makes it a valuable tool for dissecting the specific contributions of PDGFR pathways without significant off-target effects on other kinase receptors. In experimental models, CP-673451 has demonstrated the ability to reduce tumor stroma formation and enhance drug delivery by normalizing tumor vasculature. It is not used clinically but remains an important pharmacological agent in mechanistic and therapeutic development research.